Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy

Aims:  Patients with chronic hepatitis B virus (HBV) infection under entecavir (ETV) treatment develop resistant mutants with viral rebound. Here, we report an interesting case of spontaneous loss of HBV‐DNA and seroconversion following an acute flare after the development of ETV‐resistant mutants. This patient received ETV after lamivudine breakthrough.

[1]  J. Goldberg,et al.  Helicobacter pylori and mitogen‐activated protein kinases regulate the cell cycle, proliferation and apoptosis in gastric epithelial cells , 2008, Journal of gastroenterology and hepatology.

[2]  R. Colonno,et al.  Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. , 2008, Journal of hepatology.

[3]  C. Mazzucco,et al.  Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance , 2008, Hepatology.

[4]  Ping-Chang Yang,et al.  Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. , 2008, World journal of gastroenterology.

[5]  E. Keeffe,et al.  Chronic hepatitis B: preventing, detecting, and managing viral resistance. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  N. Ikuta,et al.  Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case , 2007, Journal of gastroenterology and hepatology.

[7]  U. Iloeje,et al.  Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. , 2008, Journal of managed care pharmacy : JMCP.

[8]  M. Buti,et al.  Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment‐naive patients , 2007, Journal of viral hepatitis.

[9]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[10]  G. Yao.  Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. , 2007, The Journal of antimicrobial chemotherapy.

[11]  N. Warner,et al.  The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro , 2007, Antimicrobial Agents and Chemotherapy.

[12]  J. Villeneuve,et al.  Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.

[13]  D. Snydman.  Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD AI463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .

[14]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[15]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[16]  Y. Liu,et al.  Evolution of multi‐drug resistant hepatitis B virus during sequential therapy , 2006, Hepatology.

[17]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[18]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[19]  R. Gieschke,et al.  A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon-α2A, Lamivudine and Combination Therapy , 2005, Antiviral therapy.

[20]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[21]  T. Trikalinos,et al.  Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B , 2005 .

[22]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[23]  T. Trikalinos,et al.  Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. , 2005, World journal of gastroenterology.

[24]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[25]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[26]  Y. Liaw,et al.  C ASE R EPORT: Dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B , 1999 .

[27]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[28]  S. Günther,et al.  Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. , 1999, Journal of hepatology.

[29]  Y. Liaw,et al.  Case report: dramatic response to lamivudine therapy following corticosteroid priming in chronic hepatitis B. , 1999, Journal of Gastroenterology and Hepatology.